Individual research recommendation details

Recommendation ID

NG191/8

Question

What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

Any explanatory notes
(if applicable)

Suggested PICO (Population, Intervention, Comparator, Outcome)

P: hospitalised people with COVID-19
I: treatment with a combination of casirivimab and imdevimab
C:
• treatment in people with different clinical characteristics (for example, people who are seropositive, of unknown serostatus,
immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to
vaccination status or history of natural infection)
O:
• mortality
• progression to invasive mechanical ventilation
• progression to non-invasive respiratory support
• duration of hospitalisation
• adverse events
• costs of treatment
• health-related quality of life

Source guidance details

Comes from guidance

COVID-19 rapid guideline: managing COVID-19

Number

NG191

Date issued

March 2021

Other details